RIC3 Antibody
Description
Introduction to RIC3 Antibody
The RIC3 antibody is a specialized immunological reagent designed to detect and study the RIC3 protein, a molecular chaperone critical for the proper assembly and surface trafficking of specific nicotinic acetylcholine receptors (nAChRs) and serotonin receptors . RIC3 (resistant to inhibitors of cholinesterase 3) is an endoplasmic reticulum (ER)-localized transmembrane protein with conserved structural features across species, including a cleavable signal peptide, a single transmembrane domain, and a cytoplasmic coiled-coil domain essential for its chaperone function . Antibodies targeting RIC3 are pivotal in elucidating its role in receptor biogenesis, neurobiology, and disease mechanisms.
Applications in Research
RIC3 antibodies enable critical insights into receptor assembly and cellular signaling:
Receptor Biogenesis Studies
RIC3 antibodies have been instrumental in demonstrating the protein’s role in:
-
α7 nAChR Assembly: RIC3 binds unfolded and folded α7 subunits, facilitating pentamerization and ER-to-plasma membrane trafficking .
-
5-HT₃ Receptor Interactions: Co-localization studies in transfected cells revealed ER interactions between RIC3 and 5-HT₃ subunits (e.g., 5-HT₃A, -C, -D, -E) .
Pathophysiological Research
-
Neurological Disorders: RIC3 variants may influence α7 nAChR function, implicating its role in diseases like multiple sclerosis (MS) .
-
Cancer and Inflammation: Dysregulated RIC3 expression could modulate cholinergic signaling in inflammatory pathways .
Mechanistic Insights
-
Coiled-Coil Domain Dependency: RIC3’s cytoplasmic coiled-coil domain is essential for homotypic interactions and α7 nAChR assembly . Antibodies targeting this region (e.g., ABIN954548) disrupt function, confirming its critical role .
-
Subunit-Specific Effects: RIC3 increases α7 subunit folding/assembly but stabilizes α4/β2 subunits without altering their assembly, highlighting receptor-specific mechanisms .
Clinical Relevance
-
Neuroinflammation: RIC3-mediated α7 nAChR modulation could regulate immune responses, offering therapeutic targets for neurodegenerative diseases .
-
Cancer Metastasis: Dysregulated RIC3 expression may influence cholinergic signaling in tumors, though direct evidence remains limited .
Challenges and Considerations
-
Isoform Complexity: RIC3 exists in full-length and truncated isoforms (lacking coiled-coil domains), necessitating epitope-specific antibodies to avoid cross-reactivity .
-
Species-Specific Reactivity: Antibodies optimized for human RIC3 may not bind orthologs in non-mammalian models (e.g., C. elegans) .
-
Experimental Controls: Proper validation (e.g., knockdown studies) is critical to distinguish true RIC3 signals from nonspecific binding .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Basic Research Questions
What experimental approaches validate RIC3 antibody specificity in Western blotting?
To confirm specificity:
-
Perform siRNA-mediated RIC3 knockdown controls alongside untreated samples to observe band reduction
-
Use peptide blocking assays with the immunogen sequence (e.g., C-terminal residues 313-341 in humans)
-
Compare molecular weights: Full-length RIC3 migrates at ~41 kDa, while isoforms may show bands at 30-35 kDa
Example validation data from literature:
| Sample Type | Expected Band (kDa) | Observed Band (kDa) | Citation |
|---|---|---|---|
| Mouse heart | 41 | 41 | |
| Human brain lysate | 41 | 41 (major), 35 (minor) |
How does epitope location influence RIC3 antibody performance in co-immunoprecipitation (co-IP)?
Antibodies targeting cytoplasmic domains (e.g., C-terminal coiled-coil regions) are preferred for co-IP studies due to:
-
Compatibility with non-denaturing lysis buffers (e.g., 1% digitonin)
Critical consideration: Avoid antibodies against luminal regions (e.g., N-terminal residues 1-31) for co-IP, as these epitopes may be masked by ER retention signals .
What controls are essential when using RIC3 antibodies in immunohistochemistry?
-
Negative control: Tissue from RIC3 knockout models (e.g., Ric3 / - mice)
-
Isotype control: Match host species and IgG subclass (e.g., rabbit IgG for polyclonal antibodies)
-
Preabsorption control: Incubate antibody with 10x molar excess of immunogen peptide
Advanced Research Questions
How to resolve discrepancies in RIC3 detection across neuronal subtypes?
Methodological framework:
-
Subcellular fractionation: Isolate ER vs. Golgi membranes (RIC3 shows differential localization)
-
Protease protection assay: Confirm topology using Proteinase K ± 1% Triton X-100
-
Isoform-specific qPCR: Correlate mRNA splice variants (e.g., NM_001142518.1 vs NM_024557.3) with antibody reactivity
Key finding: The long isoform (369 aa) contains two coiled-coil domains critical for antibody recognition in WB, while short isoforms lack these epitopes .
What strategies identify RIC3-receptor interactions in conformational studies?
-
Toxin-binding assays: Combine 125I-α-bungarotoxin precipitation with RIC3 immunoprecipitation to distinguish folded vs. unfolded receptor complexes
-
FRET-based biosensors: Monitor real-time RIC3/α7 nAChR interactions using CFP/YFP-tagged constructs
-
Limited proteolysis-MS: Map interaction interfaces by comparing tryptic fragments in presence/absence of bound antibody
Critical data: RIC3 binds both unassembled α7 subunits (non-toxin-binding) and pentameric receptors (toxin-binding) with Kd = 0.8 ± 0.3 μM .
How to optimize RIC3 antibody use for studying chaperone redundancy?
Advanced application: Combine RIC3 staining with in situ proximity ligation assay (PLA) to quantify interactions with BARP or NACHO co-chaperones .
